Bacillus Calmette-Guerin (BCG) vaccine adverse events in Victoria, Australia: analysis of reports to an enhanced passive surveillance system

Hazel Clothier, Laine Hosking, Nigel Crawford, Melissa Russell, Mee Lee Easton, Julie-Ann Quinn, James Peter Buttery

Research output: Contribution to journalArticleResearchpeer-review

10 Citations (Scopus)

Abstract

Bacillus Calmette-Guerin (BCG) vaccine is used worldwide, with high efficacy against childhood Mycobacterium tuberculosis (TB) meningitis and miliary TB. BCG vaccine is considered safe, with serious systematic adverse events following immunization (AEFI) of immunocompetent recipients being rare, although adverse event rates vary between differing BCG strains. In Victoria, Australia, AEFI are reported to SAEFVIC (Surveillance of Adverse Events Following Vaccination In the Community), an enhanced passive surveillance system operational since 2007.
Original languageEnglish
Pages (from-to)79 - 86
Number of pages8
JournalDrug Safety
Volume38
Issue number1
DOIs
Publication statusPublished - 2015

Cite this